Bristol Myers Squibb Opdivo Qvantig revenue
Opdivo Qvantig revenue at Bristol Myers Squibb came to $334.0M for the quarter to 30 Sep 2026, up 398.5% from a year earlier.
As Bristol Myers Squibb reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 29 Oct 2026.
By quarter
| Period ending | Opdivo Qvantig revenue | Change on a year | Filed |
|---|---|---|---|
| 30 Sep 2026 | $334.0M | up 398.5% | 29 Oct 2026 |
| 30 Jun 2026 | $261.0M | up 770.0% | 30 Jul 2026 |
| 31 Mar 2026 | $163.0M | up 1711.1% | 30 Apr 2026 |
| 30 Sep 2025 | $67.0M | — | 30 Oct 2025 |
| 30 Jun 2025 | $30.0M | — | 31 Jul 2025 |
| 31 Mar 2025 | $9.0M | — | 24 Apr 2025 |
| 31 Dec 2024 | $0 | — | 12 Feb 2025 |
| 30 Sep 2024 | $0 | — | 31 Oct 2024 |
| 30 Jun 2024 | $0 | — | 26 Jul 2024 |
| 31 Mar 2024 | $0 | — | 25 Apr 2024 |
Definition
Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.
Other operating KPIs of Bristol Myers Squibb: International revenues · Gross product sales · Net product sales · Growth Portfolio revenue · Legacy Portfolio revenue · Eliquis revenue · Opdivo revenue · Orencia revenue · Yervoy revenue · Reblozyl revenue · Breyanzi revenue · Alliance and other revenues · Camzyos revenue · Opdualag revenue · Revlimid revenue · Zeposia revenue · Pomalyst/Imnovid revenue · Abecma revenue · Sotyktu revenue · Alliance revenues · Sprycel revenue · Abraxane revenue · Krazati revenue · Cobenfy revenue · financial statements
Every KPI and segment of BMY, in the terminal.
Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.